Neoadjuvant Chemotherapy in Advanced Ovarian CancerNeoadjuvant Chemotherapy in Advanced Ovarian Cancer
Find out where neoadjuvant chemotherapy followed by interval debulking fits in the treatment scheme for epithelial ovarian cancer. Therapeutic Advances in Medical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Lynparza™ approved in the EU as first-in-class treatment for advanced BRCA-mutated ovarian cancer
AstraZeneca announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 18, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Oncology BRCA-mutated Latest News olaparib ovarian cancer platinum-based chemotherapy Source Type: news
Breast Cancer History, Please Don't Repeat
I don't have breast cancer.
I've waited to hear those words for nearly six months, after a suspicious mammogram led to a host of other tests and procedures. Each round of results revealed more about what was causing the abnormalities. Ultimately I discovered that I have two conditions that generate atypical cells and put me at increased risk for breast cancer.
Genetically I'm already predisposed, since my mom died from it at age 46. Because of her early death, I had my first mammogram at age 29. I've long paid close attention to the health of my breasts. For years I figured my small size meant I couldn't possibly face ...
Source: Healthy Living - The Huffington Post - December 5, 2014 Category: Consumer Health News Source Type: news
Molecular Analysis of Human Papillomavirus Virus-Like Particle Activated Langerhans Cells In Vitro
Langerhans cells (LC) are the resident antigen-presenting cells in human epithelium, and are therefore responsible for initiating immune responses against human papillomaviruses (HPV) entering the epithelial and mucosal layers in vivo. Upon proper pathogenic stimulation, LC become activated causing an internal signaling cascade that results in the up-regulation of co-stimulatory molecules and the release of inflammatory cytokines. Activated LC then migrate to lymph nodes where they interact with antigen-specific T cells and initiate an adaptive T-cell response. However, HPV manipulates LC in a suppressive manner that alter...
Source: Springer protocols feed by Cancer Research - November 12, 2014 Category: Cancer & Oncology Source Type: news
Replication of Human Papillomavirus in Culture
Human papillomaviruses (HPV) are the major factor in causing cervical cancer as well as being implicated in causing oral and anal cancers. The life cycle of HPV is tied to the epithelial differentiation system, as only native virus can be produced in stratified human skin. Initially, HPV research was only possible utilizing recombinant systems in monolayer culture. With new cell culture technology, systems using differentiated skin have allowed HPV to be studied in its native environment. Here, we describe current research studying native virions in differentiated skin including viral assembly, maturation, capsid protein i...
Source: Springer protocols feed by Cancer Research - November 12, 2014 Category: Cancer & Oncology Source Type: news
Artificial Intelligence Predicts Survival in Epithelial Ovarian Cancer
Radiomic Prognostic Vector IDs patients with median overall survival of less than two years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Radiology, Journal, Source Type: news
Adding HIPEC to Cytoreductive Surgery Beneficial in Ovarian CA
Longer survival with hyperthermic intraperitoneal chemotherapy in stage III epithelial ovarian cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Surgery, Journal, Source Type: news
MD Anderson's David M. Gershenson, MD, Receives IGCS's Award for Excellence in Gynecologic Oncology
For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence.
Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.The IGCS is a not-for-prof...
Source: M. D. Anderson Cancer Center - News Releases - November 10, 2014 Category: Cancer & Oncology Source Type: news
Scientists develop new way to study how human cells become immortal, a crucial precursor to cancer
(DOE/Lawrence Berkeley National Laboratory) Berkeley Lab scientists have developed a new method that can easily create immortal human mammary epithelial cells. The cells could greatly facilitate the examination of cell immortalization as it actually occurs during cancer progression. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 6, 2014 Category: Biology Source Type: news
Lynparza™ (olaparib) receives positive CHMP opinion in the EU
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 24, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology BRCA-mutated Latest News Lynparza olaparib ovarian cancer Source Type: news
MiR-7 Promotes Epithelial Cell Transformation by Targeting the Tumor Suppressor KLF4
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression and their misregulation is common in different types of cancer.09/03/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 3, 2014 Category: Cancer & Oncology Source Type: news
Carboplatin Remains the Best Chemotherapy Drug for HIPEC Procedure
Surgeon Brian Loggie, M.D., hopes to end the continued debate over which chemotherapy agent is the best to use during the HIPEC procedure that he helped pioneer for peritoneal mesothelioma patients.
There is no doubt in his mind: Carboplatin.
The American Surgeon recently published a retrospective study in which Loggie and his colleagues at the Creighton University Medical Center concluded that carboplatin clearly was more effective than mitomycin, which several cancer centers are using.
The HIPEC (Hyperthermic Intraperitoneal Chemotherapy) procedure involves the internal rinsing or bathing of the abdominal area with a ch...
Source: Asbestos and Mesothelioma News - August 27, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
Device monitors key step in development of tumor metastases
A microfluidic device may help study key steps in the process by which cancer cells break off from a primary tumor to invade other tissues and form metastases. "This device gives us a platform to be used in testing and comparing compounds to block or delay the epithelial-mesenchymal transition, potentially slowing the progression of cancer," says one researcher. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2014 Category: Science Source Type: news
Simple, New Blood Test Could Lead to Earlier Mesothelioma Treatment
A new blood test developed in Japan is raising hopes it can more accurately diagnose mesothelioma, leading to earlier cancer treatment and improved chances of survival.
The test involves a protein biomarker in the blood called N-ERC/mesothelin and a new enzyme-linked system for detecting it. This biomarker is overly expressed in patients with the asbestos-related cancer.
Researchers reported their test was 95 percent accurate in identifying cases of the disease and 76 percent accurate in ruling it out. Both are higher percentages than previously reported with other blood tests.
Most experts agree the key to developing bett...
Source: Asbestos and Mesothelioma News - July 31, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
Vintafolide: A Novel Targeted Epithelial Ovarian Cancer AgentVintafolide: A Novel Targeted Epithelial Ovarian Cancer Agent
Get up-to-date on trial results for this novel folate receptor (FR)-targeted agent for epithelial ovarian cancer. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
